A. O. Muck, H. Seeger and D. Wallwiener, “Inhibitory effect of statins on the proliferation of human breast cancer cells,” International Journal of Clinical Pharmacology and Therapeutics, Vol. 42, No. 12, 2004, pp. 695-700.
 R. E. Scranton, M. Young, E. Lawler, D. Solomon, D. Gagnon and J. M. Gaziano, “Statin use and fracture risk: study of a US veterans population,” Archives of Internal Medicine, Vol. 165, No. 17, 2005, pp. 2007-2012.
 G. Mundy, R. Garrett, S. Harris, J. Chan, D. Chen, G. Rosini, B. Boyce, M. Zhao and G. Gutierrez, “Stimulation of bone formation in vitro and in rodents by statins,” Science, Vol. 286, pp. 1946-1949.
 F. von Knoch, C. Wedemeyer, A. Heckelei, G. Saxler, G. Hilken, J. Brankamp, T. Sterner, S. Landgraeber, F. Henschke, F. Loer and M. von Knoch,M, “Promotion of bone formation by simvastatin in polyethylene particle-induced osteolysis,” Biomaterials, Vol. 26, No. 29, 2005, pp. 5783-5789.
 V. Viereck, C. Grundker, S. Blaschke, K-H. Frosch, M. Schopper, G. Emons and L. C. Hofbauer, “Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts,” Journal of Cellular Biochemistry, Vol. 96, No. 6, 2005, pp. 1244-1253.
 J. Fogh, J. M. Fogh and T. Orfeo, “One hundred and twenty-seven cultured human tumour cell lines producing tumours in nude mice,” Journal of the national cancer institute, Vol. 59, No.1, 1977, pp. 221-226.
 J. Kumi-Diaki, S. Saddler-Shawnette, A. Aller and J. Brown, “Potential Mechanism of Phytochemical-Induced Apoptosis in Human Prostate Adenocarcinoma Cells: Therapeutic Synergy in Genistein and B-Lapachone Combination Treatment,” Cancer Cell International, Vol. 4, No. 5, 2004, pp. 1475-2867. doi:10.1186/1475-2867-4-5
 M. R. Graaf, D. J. Richel, C. J. F. Noorden and H-J. Guchelaar, “Effects of statins and farnesyltransrease inhibitors on the development and progression of cancer,” Cancer Treatment Review, Vol. 30, 2004, pp. 609-641.
 J. P. Gratton, M. Morales-Ruiz, Y. Kureishi,, D. Fulton, K. Walsh and W. C. Sessa, “Akt down-regulation of p38 signalling provides a novel mechanism of vascular endo-thelial growth factor-mediated cytoprotection in endothelial cells,” The Journal of Biological Chemistry, Vol. 276, No. 32, 2001, pp. 30359-30365.
 Q. B. She, D. B. Solit, K. E. O'Reilly, J. Lobo and N. Rosen, “The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/AKT kinase pathways in PTEN-deficient tumour cells,” Cancer cell, Vol. 8, 2005, pp. 287-297.
 A. C. Donahue and D. A. Fruman, “PI3K signaling controls cell fate at many points in B lymphocyte development and activation,” Seminars in Cell and Developmental Biology, Vol. 15, 2004, pp. 183-197.
 T. Ravingerova, M. Barancik and M. Strniskova, “Mitogen-activated protein kinases: A new therapeutic target in cardiac pathology,” Molecular and Cellular Biochemistry, Vol. 247, 2003, pp.127-138.